Lombard Odier Asset Management (USA)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-33,362	Closed	-$164K	–	434
2024 Q1	$164K	Buy	+33,362	New	+$197K	﹤0.01%	329
2023 Q1	–	Sell	-11,177	Closed	-$206K	–	411
2022 Q4	$206K	Buy	+11,177	New	+$256K	0.01%	301
2016 Q4	–	Sell	-21,611	Closed	-$350K	–	256
2016 Q3	$350K	Sell	21,611 -904	-4%	-$13.1K	0.03%	230
2016 Q2	$306K	Buy	22,515 +6,320	+39%	+$112K	0.04%	198
2016 Q1	$283K	Sell	16,195 -214,016	-93%	-$4.36M	0.04%	151
2015 Q4	$7.86M	Buy	230,211 +5,211	+2%	+$181K	0.76%	56
2015 Q3	$6.7M	Sell	225,000 -25,000	-10%	-$759K	0.58%	55
2015 Q2	$8M	Sell	250,000 -28,568	-10%	-$735K	0.57%	46
2015 Q1	$5.78M	Buy	278,568 +27,963	+11%	+$483K	0.46%	81
2014 Q4	$4.25M	Buy	250,605 +50,710	+25%	+$886K	0.29%	94
2014 Q3	$3.86M	Buy	199,895 +49,895	+33%	+$1.3M	0.27%	106
2014 Q2	$5.1M	Buy	150,000 +50,000	+50%	+$1.57M	0.27%	102
2014 Q1	$3.15M	Buy	+100,000	New	+$3.12M	0.12%	143

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s RVNC Position: Q2 2024 in Review

Lombard Odier Asset Management (USA) sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 33,362 shares — an estimated $164K sold.

Lombard Odier Asset Management (USA) first reported a position in RVNC in Q1 2014 and held it in 13 quarters. The position peaked at $8M in Q2 2015. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

Lombard Odier Asset Management (USA) reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 33,362 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $164K.
Lombard Odier Asset Management (USA) first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 13 quarters.
Lombard Odier Asset Management (USA)'s Revance Therapeutics, Inc. position peaked at $8M in Q2 2015.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q2 2024, filed 14 Aug 2024.